Anti-TGF-β antibody, 1D11, ameliorates glomerular fibrosis in mouse models after the onset of proteinuria

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Liang, Xiaoyan ^a   Schnaper, H William ^a   Matsusaka, Taiji ^b   Pastan, Ira ^c   Ledbetter, Steve ^d   Hayashida, Tomoko ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TOKAI UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; COL1A2 PROTEIN; COLLAGEN TYPE 1; CREATININE; DOXORUBICIN; FIBRONECTIN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D11; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADRIAMYCIN-INDUCED NEPHROPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL GLOMERULONEPHRITIS; GENE EXPRESSION; GLOMERULAR FIBROSIS; GLOMERULUS BASEMENT MEMBRANE; KIDNEY FIBROSIS; MALE; MOUSE; MOUSE MODEL; NEP25 PODOCYTE ABLATION NEPHROPATHY; NONHUMAN; PODOCYTE; PROTEINURIA; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GLOMERULUS; KIDNEY DISEASES; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOMARKERS; DISEASE MODELS, ANIMAL; DOXORUBICIN; FIBROSIS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; MICE; PODOCYTES; PROTEINURIA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84969528714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155534     Document Type: Article

References (63)

1. Bottinger EP. TGF-β in renal injury and disease. Semin Nephrol. 2007; 27:309-320. PMID: 17533008
2. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest. 1993; 92:2597-2601. PMID: 8254017
3. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP, et al. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab Invest. 1996; 74:991-1003. PMID: 8667617
4. Mozes MM, Bottinger EP, Jacot TA, Kopp JB. Renal expression of fibrotic matrix proteins and of transforming growth factor-β isoforms in TGF-β transgenic mice. J Am Soc Nephrol. 1999; 10:271-280. PMID: 10215326
5. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. Integration of TGF-β /Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO. 2004; 23:1155-1165.
6. Cichon MA, Radisky DC. Extracellular matrix as a contextual determinant of transforming growth factor-β signaling in epithelial-mesenchymal transition and in cancer. Cell Adh Migr. 2014; 8:588-594. doi: 10.4161/19336918.2014.972788 PMID: 25482625
7. Goumenos DS, Tsakas S, El Nahas AM, Alexandri S, Oldroyd S, Kalliakmani P, et al. Transforming growth factor-β 1 in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant. 2002; 17:2145-2152. PMID: 12454225
8. Murakami K, Takemura T, Hino S, Yoshioka K. Urinary transforming growth factor-β in patients with glomerular diseases. Pediatr Nephrol. 1997; 11:334-336. PMID: 9203185
9. Woroniecki RP, Shatat IF, Supe K, Du Z, Kaskel FJ. Urinary cytokines and steroid responsiveness in idiopathic nephrotic syndrome of childhood. Am J Nephrol. 2008; 28:83-90. PMID: 17914249
10. Kim JH, Kim BK, Moon KC, Hong HK, Lee HS. Activation of the TGF-β/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int. 2003; 64:1715-1721. PMID: 14531804
11. Wasilewska AM, Zoch-Zwierz WM. Transforming growth factor-β1 in nephrotic syndrome treated with cyclosporine and ACE inhibitors. Pediatr Nephrol. 2004; 19:1349-1353. PMID: 15490252
12. Suthanthiran M, Gerber LM, Schwartz JE, Sharma VK, Medeiros M, Marion R, et al. Circulating transforming growth factor-β1 levels and the risk for kidney disease in African Americans. Kidney Int. 2009; 76:72-80. doi: 10.1038/ki.2009.66 PMID: 19279557
13. Wong MG, Perkovic V, Woodward M, Chalmers J, Li Q, Hillis GS, et al. Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int. 2013; 83:278-284. doi: 10.1038/ki.2012.383 PMID: 23235570
14. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature. 1990; 346:281-284. PMID: 2374594
15. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature. 1992; 360:361-364. PMID: 1280332
16. Schievenbusch S, Strack I, Scheffler M, Wennhold K, Maurer J, Nischt R, et al. Profiling of anti-fibrotic signaling by hepatocyte growth factor in renal fibroblasts. Biochem Biophys Res Commun. 2009; 385:55-61. doi: 10.1016/j.bbrc.2009.05.010 PMID: 19426716
17. Ka SM, Huang XR, Lan HY, Tsai PY, Yang SM, Shui HA, et al. Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol. 2007; 18:1777-1788. PMID: 17475816
18. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996; 45:522-530. PMID: 8603776
19. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci U.S.A. 2000; 97:8015-8020. PMID: 10859350
20. Finer G, Schnaper HW, Kanwar YS, Liang X, Lin HY, Hayashida T. Divergent roles of Smad3 and PI3-kinase in murine adriamycin nephropathy indicate distinct mechanisms of proteinuria and fibrogenesis. Kidney Int. 2012; 82:525-536. doi: 10.1038/ki.2012.139 PMID: 22534961
21. Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, et al. Gene therapy by transforming growth factorβ receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. 1999; 55:465-475. PMID: 9987071
22. Kasuga H, Ito Y, Sakamoto S, Kawachi H, Shimizu F, Yuzawa Y, et al. Effects of anti-TGF-β type II receptor antibody on experimental glomerulonephritis. Kidney Int. 2001; 60:1745-1755. PMID: 11703592
23. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor β. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol. 1989; 142:1536-1541. PMID: 2537357
24. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, et al. Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol. 2003; 14:1816-1824. PMID: 12819241
25. Benigni A, Zoja C, Campana M, Corna D, Sangalli F, Rottoli D, et al. Beneficial effect of TGF-β antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol. 2006; 104:e158-168. PMID: 16902320
26. Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA. Combining TGF- β inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int. 2004; 66:1774-1784. PMID: 15496148
27. Lavoie P, Robitaille G, Agharazii M, Ledbetter S, Lebel M, Lariviere R. Neutralization of transforming growth factor-β attenuates hypertension and prevents renal injury in uremic rats. J Hypertens. 2005; 23:1895-1903. PMID: 16148614
28. Murphy SR, Dahly-Vernon AJ, Dunn KM, Chen CC, Ledbetter SR, Williams JM, et al. Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats. Am J Physiol, Regul Integr Comp Physiol. 2012; 303:R57-69.
29. Miyajima A, Chen J, Lawrence C, Ledbetter S, Soslow RA, Stern J, et al. Antibody to transforming growth factor-β ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int. 2000; 58:2301-2313. PMID: 11115064
30. Ling H, Li X, Jha S, Wang W, Karetskaya L, Pratt B, et al. Therapeutic role of TGF-β -neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol. 2003; 14:377-388. PMID: 12538738
31. Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H, et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol. 2005; 16:1013-1023. PMID: 15758046
32. Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res. 1998; 58:968-975. PMID: 9500458
33. Kanwar YS, Liu ZZ, Kumar A, Usman MI, Wada J, Wallner EI. D-glucose-induced dysmorphogenesis of embryonic kidney. J Clin Invest. 1996; 98:2478-2488. PMID: 8958210
34. Edgley AJ, Gow RM, Kelly DJ. Laser-capture microdissection and pressure catapulting for the analysis of gene expression in the renal glomerulus. Methods Mol Biol. 2010; 611:29-40. doi: 10.1007/978-1-60327-345-9-3 PMID: 19960320
35. Hanna C, Hubchak SC, Liang X, Rozen-Zvi B, Schumacker PT, Hayashida T, et al. Hypoxia-inducible factor-2α and TGF-β signaling interact to promote normoxic glomerular fibrogenesis. Am J Phsiol, Renal Physiol. 2013; 305:F1323-1331.
36. Jeansson M, Bjorck K, Tenstad O, Haraldsson B. Adriamycin alters glomerular endothelium to induce proteinuria. J Am Soc Nephrol. 2009; 20:114-122. doi: 10.1681/ASN.2007111205 PMID: 19073829
37. Sun YB, Qu X, Zhang X, Caruana G, Bertram JF, Li J. Glomerular endothelial cell injury and damage precedes that of podocytes in adriamycin-induced nephropathy. PloS one. 2013; 8:e55027. doi: 10. 1371/journal.pone.0055027 PMID: 23359116
38. Cao Q, Wang Y, Wang XM, Lu J, Lee WSV, Yw Q, et al. Renal F4/80+ CD11c+ mononuclear phagocytes display phenotypic and functional characteristics of macrophages in health and in adriamycin nephropathy. J Am Soc Nephrol. 2015; 26:349-363. doi: 10.1681/ASN.2013121336 PMID: 25012165
39. Schnaper HW, Kopp JB. Nephrotic syndrome and the podocytopathies: minimal change nephropathy, focal segmental glomerulosclerosis and collapsing glomerulopathy. In: Schrier RW, Coffman TM, Falk RJ, Molitoris BA, Neilson EG, editors. Schrier's Diesase of the Kidney, 9th Edition. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1414-1521.
40. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005; 16:2941-2952. PMID: 16107576
41. Wickman L, Afshinnia F, Wang SQ, Yang Y, Wang F, Chowdhury M, et al. Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases. J Am Soc Nephrol. 2013; 24:2081-2095. doi: 10.1681/ASN.2013020173 PMID: 24052633
42. Zhou H, Kajiyama H, Tsuji T, Hu X, Leelahavanichkul A, Vento S, et al. Urinary exosomal Wilms' tumor-1 as a potential biomarker for podocyte injury. Am J Physiol, Renal Physiol. 2013; 305:F553-559.
43. Eddy AA. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl (2011). 2014; 4:2-8.
44. Rockey DC, Bell PD, Hill JA. Fibrosis-a common pathway to organ injury and failure. N Engl J Med. 2015; 372:1138-1149. doi: 10.1056/NEJMra1300575 PMID: 25785971
45. Wang A, Ziyadeh FN, Lee EY, Pyagay PE, Sung SH, Sheardown SA, et al. Interference with TGF-β signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol. 2007; 293:F1657-1665. PMID: 17804483
46. Krag S, Osterby R, Chai Q, Nielsen CB, Hermans C, Wogensen L. TGF-β1-induced glomerular disorder is associated with impaired concentrating ability mimicking primary glomerular disease with renal failure in man. Lab Invest. 2000; 80:1855-1868. PMID: 11140698
47. Wang D, Dai C, Li Y, Liu Y. Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria. Kidney Int. 2011; 80:1159-1169. doi: 10.1038/ki.2011.255 PMID: 21832980
48. Schiffer M, Mundel P, Shaw AS, Bottinger EP. A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-β-induced apoptosis. J Biol Chem. 2004; 279:37004-37012. PMID: 15213232
49. Wada T, Pippin JW, Terada Y, Shankland SJ. The cyclin-dependent kinase inhibitor p21 is required for TGF-β1-induced podocyte apoptosis. Kidney Int. 2005; 68:1618-1629. PMID: 16164639
50. Das R, Xu S, Quan X, Nguyen TT, Kong ID, Chung CH, et al. Upregulation of mitochondrial Nox4 mediates TGF-β-induced apoptosis in cultured mouse podocytes. Am J Physiol. Renal Physiol. 2014; 306: F155-167. doi: 10.1152/ajprenal.00438.2013 PMID: 24259511
51. Chen YM, Chien CT, Hu-Tsai MI, Wu KD, Tsai CC, Wu MS, et al. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int. 1999; 56:932-943. PMID: 10469361
52. Gava AL, Freitas FP, Balarini CM, Vasquez EC, Meyrelles SS. Effects of 5/6 nephrectomy on renal function and blood pressure in mice. Int Physiol Pathophysiol Pharmacol. 2012; 4:167-173.
53. Wang HY, Yang LZ, Gu CM, Chen Y, Zhao Y, Zhao D, et al. Pathological changes, TGF-β1 expression, and the effects of hepatocyte growth factor in 5/6 nephrectomized rats. Ren Fail. 2014; 36:393-399. doi: 10.3109/0886022X.2013.867797 PMID: 24345300
54. Agarwal I, Glazer NL, Barasch E, Biggs ML, Djousse L, Fitzpatrick AL, et al. Fibrosis-related biomarkers and risk of total and cause-specific mortality: the cardiovascular health study. Am J Epidemiol. 2014; 179:1331-1339. doi: 10.1093/aje/kwu067 PMID: 24771724
55. Greka A, Mundel P. Cell biology and pathology of podocytes. Annu Rev Physiol. 2012; 74:299-323. doi: 10.1146/annurev-physiol-020911-153238 PMID: 22054238
56. Matsusaka T, Sandgren E, Shintani A, Kon V, Pastan I, Fogo AB, et al. Podocyte injury damages other podocytes. J Am Soc Nephrol. 2011; 22:1275-1285. doi: 10.1681/ASN.2010090963 PMID: 21719786
57. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int. 2010; 77:571-580. doi: 10.1038/ki.2009.424 PMID: 19924101
58. Welsh GI, Saleem MA. The podocyte cytoskeleton-key to a functioning glomerulus in health and disease. Nat Rev Nephrol. 2012; 8:14-21.
59. Blattner SM, Hodgin JB, Nishio M, Wylie SA, Saha J, Soofi AA, et al. Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury. Kidney Int. 2013; 84:920-930. doi: 10.1038/ki.2013.175 PMID: 23677246
60. Yu H, Suleiman H, Kim AH, Miner JH, Dani A, Shaw AS, et al. Rac1 activation in podocytes induces rapid foot process effacement and proteinuria. Mol Cell Biol. 2013; 33:4755-4764. doi: 10.1128/MCB. 00730-13 PMID: 24061480
61. Kriz W, Hahnel B, Hosser H, Rosener S, Waldherr R. Structural analysis of how podocytes detach from the glomerular basement membrane under hypertrophic stress. Front Endocrinol. 2014; 5:207.
62. Kriz W, Lemley KV. A Potential Role for Mechanical Forces in the Detachment of Podocytes and the Progression of CKD. J Am Soc Nephrol. 2016; 26: 258-269.
63. Ding Y, Choi ME. Regulation of autophagy by TGF-β: emerging role in kidney fibrosis. Semin Nephrol. 2014; 34:62-71 doi: 10.1016/j.semnephrol.2013.11.009 PMID: 24485031